Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib - Concepedia

Concepedia

Publication | Open Access

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib

DOI Full Paper Access

18

Citations

30

References

2017

Year

Leora Horn, Scott Gettinger, D. Ross Camidge, Egbert F. Smit, Yelena Y. Janjigian, Vincent A. Miller, William Pao, Matthias Freiwald, Jean Fan, Bushi Wang,

Abstract

NCT01090011.

References

	Year	Citations

Page 1